Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Thursday, May 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals announced that CFO Dean Schorno will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 19 at 9:30 a.m. ET in New York. This event reflects Rigel's commitment to engaging with the investment community and discussing its advancements in hematologic disorders and cancer treatments.
Price reaction · baseline $32.13 (2026-05-13 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel Pharmaceuticals is actively engaging with investors.
  • The presentation at a major healthcare conference highlights Rigel's visibility.
  • The company focuses on improving therapies for serious health conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.,May 14, 2026/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET in New York, NY.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website atwww.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About RigelRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.

Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232[email protected]

Media:David RosenArgot Partners646.461.6387[email protected]

Frequently Asked Questions

When will Rigel present at the RBC Capital Markets Conference?

Rigel will present on May 19, 2026, at 9:30 a.m. ET.

Who will represent Rigel at the conference?

CFO Dean Schorno will present the company overview.

How can I access the presentation?

The presentation can be accessed via the Investor Relations section on Rigel's website.

What is the focus of Rigel Pharmaceuticals?

Rigel focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals healthcare conference biotechnology hematologic disorders
Last updated: May 14, 2026

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →